Do Avandia Benefits Outweigh Risks? AHRQ, Consumer Reports Are Skeptical
Executive Summary
An Agency for Healthcare Research & Quality report concluding thiazolidinediones are no more efficacious than metformin could put formulary pressure on the two marketed products in the class -GlaxoSmithKline's Avandia (rosiglitazone) and Lilly/Takeda's Actos (pioglitazone)